Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

Tigecycline is a novel 9-t-butylglycylamido derivative of minocycline that has demonstrated activity against a variety of Gram-positive and -negative bacterial pathogens. In vitro activity of tigecycline and comparator agents was determined for 3498 recent (2000-2003) strains of Staphylococcus aureus recovered from patients with either nosocomial or community-acquired infections. Oxacillin-susceptible and -resistant S. aureus from both patient populations displayed identical results for tigecycline (MIC50 and MIC90 results at 0.25 and 0.5 mg/L, respectively) and all strains were inhibited by I mg/L or less. While co-resistances to other antimicrobial classes were present in oxacillin-resistant strains, susceptibility to figecycline remained unaffected, making the compound an attractive candidate for treatment of serious hospital as well as community-acquired staphylococcal infections. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.